Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Prothena: Q2 Earnings Snapshot AP - Thu Aug 8, 4:33PM CDT

Prothena: Q2 Earnings Snapshot

PRTA : 16.65 (-2.06%)
Prothena Reports First Quarter 2023 Financial Results and Business Highlights Business Wire - Thu May 4, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial...

PRTA : 16.65 (-2.06%)
Prothena to Report First Quarter 2023 Financial Results on May 4 Business Wire - Thu Apr 27, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 16.65 (-2.06%)
Prothena to Participate in 2023 Bank of America Healthcare Conference Business Wire - Mon Apr 24, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 16.65 (-2.06%)
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial Business Wire - Thu Apr 13, 2023

Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety...

PRTA : 16.65 (-2.06%)
WBA : 9.46 (unch)
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023 Business Wire - Fri Mar 31, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new...

PRTA : 16.65 (-2.06%)
Prothena to Participate in Stifel 2023 Virtual CNS Days Business Wire - Tue Mar 21, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 16.65 (-2.06%)
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode FinancialNewsMedia - Wed Mar 15, 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 15, 2023 – USA News Group  –  According to a 2022 study of more than 6 million patients 65 and older, the risk factor...

MRVL.VN : 0.135 (+12.50%)
BIIB : 173.79 (-0.12%)
PRTA : 16.65 (-2.06%)
ITCI : 86.54 (+2.11%)
RHHBY : 39.2600 (+1.16%)
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting Business Wire - Tue Mar 14, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced broad...

PRTA : 16.65 (-2.06%)
With Alzheimer’s Cases Set to Explode in the Near-Term, New Treatments and Diagnostics are Needed BayStreet.ca - Tue Mar 14, 2023

USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for developing Alzheimer’s disease increases by 50-80% in older adults who caught COVID-19....

MRVL.VN : 0.135 (+12.50%)
BIIB : 173.79 (-0.12%)
PRTA : 16.65 (-2.06%)
ITCI : 86.54 (+2.11%)
RHHBY : 39.2600 (+1.16%)

Barchart Exclusives

McDonald's Hikes Its Dividend 6% - MCD Stock's 2.40% Yield Attracts Value Buyers Barchart - 45 minutes ago
McDonald's Corp. reported lower global comp sales and its recent E. coli outbreak pushed MCD stock down. These could be temporary issues. The good news is that it hiked the dividend by 6%, and MCD looks attractive historically. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot